Appliance manufacturer Gree bought $89m of shares in an initial public offering in which the oncology therapy developer floated at the top of its range.

China-based cancer treatment developer Kintor Pharmaceutical has raised HK$1.86bn ($240m) in an initial public offering featuring an $89m cornerstone investment by appliance manufacturer Gree, DealStreetAsia has reported.

Gree’s funding formed part of a $115m cornerstone investment in which it was joined by healthcare investment firm Highlight Capital and mutual fund Foresight Fund.

The company issued approximately 92.4 million shares on the Hong Kong Stock Exchange priced at the top of the IPO’s HK$17.80 to HK$20.15 range.

Kintor’s lead product candidate…

Robert Lavine

Robert Lavine is special features editor for Global Venturing.